基于索拉非尼的联合治疗对晚期肝癌的疗效观察  

Efficacy of sorafenib combined other therapies for advanced hepatocellular carcinoma

作　　者：夏锋[1] 孙振凯[1] 马宽生[1] 李晓武[1] 王曙光[1] 别平[1] 

机构地区：[1]第三军医大学西南医院全军肝胆外科研究所,重庆400038

出　　处：《临床肿瘤学杂志》2010年第4期365-367,共3页Chinese Clinical Oncology

摘　　要：目的观察基于索拉非尼联合多种治疗手段综合治疗晚期肝癌的疗效。方法2008年12月至2009年12月共8例患者应用索拉非尼联合其它3种以上的治疗方法,如TACE、射频消融、放射性粒子植入、三维适形放疗和免疫治疗。按照RECIST标准对其疗效进行评价。结果8例患者用4种治疗方法的4例,5种3例,6种1例。疗效评估获PR3例,SD4例,PD1例。所有患者的毒副反应均经对症处理后缓解,无严重不良反应发生。结论基于索拉非尼的联合多种治疗手段的综合治疗模式可提高晚期肝癌的疗效。Objective To evaluate efficacy of sorafenib combined other therapies for advanced hepatocellular carcinoma.Methods Eight patients with advanced HCC received at least three kinds of therapies besides sorafenib including TACE,radio-frequency ablation,radioactive seed-（125）I implantation,three-dimensional conformal radiotherapy and immunotherapy.Curative effect was evaluated by RECIST criteria.Results There were 4 patients received 4 kinds of therapies,3 patients with 5 kinds,1 patient with 6 kinds.Three patients achieved PR,4 patients achieved SD,and 1 patient achieved PD.No severe side effects occurred for 8 patients.Conclusion Synthesis treatment combined sorafenib with other therapies can improve the curative effect for advanced hepatocellular carcinoma.

关 键 词：索拉非尼 肝癌 综合治疗 分子靶向治疗 

分 类 号：R735.7[医药卫生—肿瘤]